142 related articles for article (PubMed ID: 23737087)
41. Latest FDA-approved drug nirsevimab-alip (Beyfortus): A gamechanger for treatment of respiratory syncytial virus.
Talha M; Ali MH
J Med Virol; 2023 Oct; 95(10):e29169. PubMed ID: 37815045
[No Abstract] [Full Text] [Related]
42. A Retrospective Public Health Assessment and Management in Terms of the Social and Clinical Risk Factors of Respiratory Syncytial Virus Infection in Northern Canada.
Sharif Sheikh S; Sharif H; Sharif N
Cureus; 2024 Feb; 16(2):e53378. PubMed ID: 38435208
[TBL] [Abstract][Full Text] [Related]
43. Nirsevimab (Beyfortus) for prevention of severe RSV disease in young children.
Med Lett Drugs Ther; 2023 Sep; 65(1685):145-147. PubMed ID: 37682698
[No Abstract] [Full Text] [Related]
44. Corrigendum: Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada.
Mercier E; Pisharody L; Guy F; Wan S; Hegazy N; D'Aoust PM; Kabir MP; Nguyen TB; Eid W; Harvey B; Rodenburg E; Rutherford C; Mackenzie AE; Willmore J; Hui C; Paes B; Delatolla R; Thampi N
Front Public Health; 2024; 12():1354693. PubMed ID: 38333738
[TBL] [Abstract][Full Text] [Related]
45. Respiratory syncytial virus and palivizumab: Where are we in 2014?
Robinson J
Can J Infect Dis Med Microbiol; 2014; 25(1):11-2. PubMed ID: 24634681
[No Abstract] [Full Text] [Related]
46. Myositis "Diaphragm Cramp" as a Potential Cause of Respiratory Arrests in Infants. Comment on Salfi, N.C.M. et al. Fatal Deterioration of a Respiratory Syncytial Virus Infection in an Infant with Abnormal Muscularization of Intra-Acinar Pulmonary Arteries: Autopsy and Histological Findings.
Gebien DJ
Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786359
[TBL] [Abstract][Full Text] [Related]
47. Rapid review showed that real-world results on how nirsevimab prevented respiratory syncytial virus hospitalisations were similar to randomised trials.
Kuitunen I; Renko M
Acta Paediatr; 2024 May; ():. PubMed ID: 38780142
[No Abstract] [Full Text] [Related]
48. Respiratory syncytial virus infections - recent developments providing promising new tools for disease prevention.
Broberg EK; Nohynek H
Euro Surveill; 2023 Dec; 28(49):. PubMed ID: 38062943
[No Abstract] [Full Text] [Related]
49. Biological basis of child health 5: development of the respiratory system and elements of respiratory assessment.
Crawford D; Davies K
Nurs Child Young People; 2020 Aug; ():. PubMed ID: 33104299
[TBL] [Abstract][Full Text] [Related]
50. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?
Law B; Macdonald N; Langley J; Mitchell I; Stephens D; Wang E; Robinson J; Boucher F; McDonald J; Dobson S
Paediatr Child Health; 1998 Nov; 3(6):402-4. PubMed ID: 20401222
[No Abstract] [Full Text] [Related]
51. Correction to: Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children.
Zhang XL; Zhang X; Hua W; Xie ZD; Liu HM; Zhang HL; Chen BQ; Chen Y; Sun X; Xu Y; Shu SN; Zhao SY; Shang YX; Cao L; Jia YH; Lin LN; Li J; Hao CL; Dong XY; Lin DJ; Xu HM; Zhao DY; Zeng M; Chen ZM; Huang LS
World J Pediatr; 2024 Feb; ():. PubMed ID: 38402517
[No Abstract] [Full Text] [Related]
52. Recommendations of the Spanish Society of Neonatology for the prevention of severe respiratory syncytial virus infections with nirsevimab, for the 2023-2024 season.
Sánchez Luna M; Fernández Colomer B; Couce Pico ML;
An Pediatr (Engl Ed); 2023 Oct; 99(4):264-265. PubMed ID: 37739825
[No Abstract] [Full Text] [Related]
53. Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt.
De Luca D; Sanchez-Luna M; Schettler K; Bont L; Baraldi E
Lancet Reg Health Eur; 2023 Nov; 34():100753. PubMed ID: 37927432
[No Abstract] [Full Text] [Related]
54. Pregnant patients with respiratory syncytial virus infection: assessment of characteristics and maternal morbidity at delivery.
Cox KR; Mandelbaum RS; Brueggmann D; Ouzounian JG; Matsuo K
AJOG Glob Rep; 2024 Feb; 4(1):100289. PubMed ID: 38090541
[No Abstract] [Full Text] [Related]
55. Probiotics may be considered for children and adults with cystic fibrosis.
Hill J; Smith C; Clegg A
Evid Based Nurs; 2020 May; ():. PubMed ID: 32404349
[No Abstract] [Full Text] [Related]
56. Lethal Respiratory Syncytial Virus in Zambia Is Sensitive to Long-acting Monoclonal Antibodies.
Langedijk AC; Vrancken B; Lebbink RJ; Evers A; Pieciak RC; Lemey P; Bont LJ; Gill CJ
Pediatr Infect Dis J; 2023 Nov; 42(11):e421-e423. PubMed ID: 37523582
[No Abstract] [Full Text] [Related]
57. Respiratory syncytial virus infection in COVID-19 times: Trick or threat?
Menasalvas Ruiz AI
Enferm Infecc Microbiol Clin; 2023; 41(6):319-320. PubMed ID: 37273943
[No Abstract] [Full Text] [Related]
58. Author Correction: Qualitative analysis and chaotic behavior of respiratory syncytial virus infection in human with fractional operator.
Jamil S; Bariq A; Farman M; Nisar KS; Akgül A; Saleem MU
Sci Rep; 2024 Feb; 14(1):3633. PubMed ID: 38351207
[No Abstract] [Full Text] [Related]
59. Video based Direct Observation Physiotherapy (VDOP) in children with cystic fibrosis: A randomized controlled trial.
Agarwal S; Ram Jat K; Gupta S; Sankar J; Lodha R; Kabra SK
Eur Respir J; 2024 May; ():. PubMed ID: 38811042
[No Abstract] [Full Text] [Related]
60. Microbiological processing of respiratory specimens from patients with cystic fibrosis.
Recommendations of the Clinical Subcommittee of the Medical/Scientific Advisory Committee of the Canadian Cystic Fibrosis Foundation
Can J Infect Dis; 1993 May; 4(3):166-9. PubMed ID: 22346442
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
